Articles that met the inclusion criteria and provided a definition of polypharmacy were included. One author (NM) conducted the initial database search and primary screening of article titles and abstracts and articles were categorised as: relevant, irrelevant or unsure. Three reviewers (NM, SS, GC) discussed the appropriateness of inclusion of each article classed as relevant or unsure. Once all relevant articles were identified, one author (NM) reviewed full texts of all identified articles and extracted the data. A pre-defined data extraction template was developed by all authors and then applied to ensure consistent data extraction from each of the identified studies. Data items extracted included the definitions of polypharmacy and associated terms such as minor, moderate and excessive polypharmacy and whether studies distinguished between appropriate and inappropriate polypharmacy and if so, how this distinction was made or defined. The definitions of polypharmacy and associated terms were categorised as: i. numerical only (using the number of medications to define polypharmacy), ii. numerical for a given duration of therapy or healthcare setting for e.g. during hospital stay or iii. Descriptive (using a brief description to define polypharmacy). Once the primary data extraction was complete all authors reviewed the content analysis for each of the extracted studies, with data further categorised and summarised in tables.
>
Procedures
>
Therapeutic or Preventive Procedure
>
Polypharmacy
Polypharmacy
Polypharmacy is the concurrent use of multiple medications by a patient, often associated with older adults and individuals with chronic conditions.
This complex medical issue can lead to adverse drug interactions, increased risk of side effects, and reduced medication adherence.
Effective management of polypharmacy requires careful consideration of patient-specific factors, medication interactions, and the potential benefits and risks of each prescription.
Healthcare providers play a crucial role in optimizing polypharmacy through regular medication reviews, patient education, and coordinated care.
Reasearch in this area focuses on developing tools and strategies to help identify and mitigate the challenges of polypharmacy, with the ultimate goal of improving patient outcomes and quality of life.
This complex medical issue can lead to adverse drug interactions, increased risk of side effects, and reduced medication adherence.
Effective management of polypharmacy requires careful consideration of patient-specific factors, medication interactions, and the potential benefits and risks of each prescription.
Healthcare providers play a crucial role in optimizing polypharmacy through regular medication reviews, patient education, and coordinated care.
Reasearch in this area focuses on developing tools and strategies to help identify and mitigate the challenges of polypharmacy, with the ultimate goal of improving patient outcomes and quality of life.
Most cited protocols related to «Polypharmacy»
Aged
cDNA Library
Drug Interactions
Drug Kinetics
Drug Reaction, Adverse
Drugs, Non-Prescription
Face
Pharmaceutical Preparations
Pharmacotherapy
Polypharmacy
Safety
The reporting of this systematic review conforms to the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) checklist.
MEDLINE (Ovid), EMBASE and Cochrane databases were searched between 1st January 2000 and 30th May 2016.
The following search terms (Medical Subject Headings or MESH and keywords) were used in EMBASE and MEDLINE (Ovid):
polypharmacy/ (MESH) OR multiple medication* OR multiple medicine* OR multiple drug* (key words) OR many medication* OR many medicine* OR many drug* (key words) (for all articles referring to polypharmacy) AND.
defin* (key word) or explan* (keyword) (for all articles defining or explaining polypharmacy).
For the review of the Cochrane database, the term “polypharmacy” was searched.
The search was limited to primary research articles which defined the term polypharmacy in any shape or form, conducted in humans and published in English between the years 2000 and 2016. Articles were considered if the abstracts were available in English and were published or in press. Reference lists of relevant articles and grey literature were screened to identify other relevant articles. The search strategy was developed in consultation with a librarian specialising in health databases, with a pre-determined protocol developed collaboratively with the authors for methods to search and select relevant articles.
MEDLINE (Ovid), EMBASE and Cochrane databases were searched between 1st January 2000 and 30th May 2016.
The following search terms (Medical Subject Headings or MESH and keywords) were used in EMBASE and MEDLINE (Ovid):
polypharmacy/ (MESH) OR multiple medication* OR multiple medicine* OR multiple drug* (key words) OR many medication* OR many medicine* OR many drug* (key words) (for all articles referring to polypharmacy) AND.
defin* (key word) or explan* (keyword) (for all articles defining or explaining polypharmacy).
For the review of the Cochrane database, the term “polypharmacy” was searched.
The search was limited to primary research articles which defined the term polypharmacy in any shape or form, conducted in humans and published in English between the years 2000 and 2016. Articles were considered if the abstracts were available in English and were published or in press. Reference lists of relevant articles and grey literature were screened to identify other relevant articles. The search strategy was developed in consultation with a librarian specialising in health databases, with a pre-determined protocol developed collaboratively with the authors for methods to search and select relevant articles.
Homo sapiens
Pharmaceutical Preparations
Polypharmacy
prisma
Aged
Anxiety
Cachexia
Clip
Cognition
Eating
Ethics Committees, Research
Gastrointestinal Cancer
Malignant Neoplasms
Mental Health
Neoplasms
Nurses
Nutrition Assessment
Patients
Physical Examination
Polypharmacy
Psychometrics
Satisfaction
Vision
In the first phase of this study, a literature review was conducted within OVID for original articles published between January 1997 and May 2007, using the following search terms and phrases: ‘polypharmacy,’ ‘elderly,’ ‘geriatrics,’ ‘inappropriate medication,’ and ‘multiple medication use.’ English language articles available in local holding which described ‘polypharmacy’ or the issue of the simultaneous use of multiple medications in elderly patients were evaluated. Discrete definitions of polypharmacy were identified and recorded.
Throughout the literature, numerous articles used the term ‘polypharmacy’ and the phrase ‘inappropriate drug use’ interchangeably. The research reported that methods most often used for identifying inappropriate drug use involved the use of criteria, primarily the criteria developed, and more recently revised, by Beers and colleagues (Beers 1997 (link); Fick et al 2003 (link)). The investigators adapted a list of inappropriate drugs from two primary sources for use in this study (Fick et al 2003 (link); Bressler and Bahl 2003 (link)). The medications used in this research were based upon the Beers’ criteria but were limited to those identified as “high risk” (seeTable 2 ). This list is labeled as ‘potentially inappropriate,’ because we recognize that use of one or more of these agents in an older adult could be justified by specific circumstances, for example, if safer alternatives had been exhausted.
Two different definitions of polypharmacy were applied to the database, which consisted of outpatient medical record data randomly collected by physician assistant students at the time of patient encounters during supervised clinical training from August 2006 to May 2007. Polypharmacy was defined as either “use of at least one potentially inappropriate drug” (seeTable 2 ) or “the presence of six or more concurrent medications”. The database included patient demographics (ie, age, gender, ethnicity, educational level, and marital status), vital signs, diagnoses, prescription medications, health-related quality of life, and disease-specific markers when applicable (ie, blood pressure, urine microalbumin, hemoglobin A1c, creatinine clearance, liver transaminases, estimated left ventricular ejection fraction, and others). These outpatient data were collected from more than 500 outpatient clinical sites throughout the state of South Carolina representing the following disciplines: family medicine, general internal medicine, pediatrics, general surgery, gynecology and obstetrics, emergency medicine, and internal medicine subspecialties. At the time of analysis the database contained 10,455 discrete patient entries, and the 1270 entries involving patients 65-years or older were selected for investigation.
Throughout the literature, numerous articles used the term ‘polypharmacy’ and the phrase ‘inappropriate drug use’ interchangeably. The research reported that methods most often used for identifying inappropriate drug use involved the use of criteria, primarily the criteria developed, and more recently revised, by Beers and colleagues (Beers 1997 (link); Fick et al 2003 (link)). The investigators adapted a list of inappropriate drugs from two primary sources for use in this study (Fick et al 2003 (link); Bressler and Bahl 2003 (link)). The medications used in this research were based upon the Beers’ criteria but were limited to those identified as “high risk” (see
Two different definitions of polypharmacy were applied to the database, which consisted of outpatient medical record data randomly collected by physician assistant students at the time of patient encounters during supervised clinical training from August 2006 to May 2007. Polypharmacy was defined as either “use of at least one potentially inappropriate drug” (see
Aged
Beer
Blood Pressure
Creatinine
Diagnosis
Ethnicity
Gender
Hemoglobin A, Glycosylated
Liver
Outpatients
Patients
Pharmaceutical Preparations
Physician Assistant
Polypharmacy
Prescription Drugs
Safety
Signs, Vital
Student
Transaminases
Urine
Ventricular Ejection Fraction
Most recents protocols related to «Polypharmacy»
The INCREASE study was a randomized controlled trial enrolling community-dwelling adults 65 years and older who did not have dementia and were using at least one PIM as defined in the 2015 Beers Criteria (the most recent version at the time of the study) [13 ]. Complete details of the INCREASE protocol and results are available elsewhere and briefly described below [11 (link), 12 (link)]. After 1:1 randomization that was stratified based on baseline amyloid burden, participants randomized to the control group received usual care with educational pamphlets on medication appropriateness for older adults and risks associated with polypharmacy. In addition to educational materials, participants randomized to the MTM intervention met with the BCGP and a non-pharmacist study clinician (e.g., nurse practitioner, neurologist) to discuss the baseline recommendations. This meeting allowed for 1) participant education on risks, benefits, and alternatives to optimize medication use; and 2) the collection of additional relevant information, including participant beliefs, preferences, and treatment goals. During the MTM team meeting, final recommendations were formalized, and the details of any relevant revisions to the baseline recommendation were noted in the pre-specified data collection forms.
The INCREASE study was approved by the University of Kentucky Institutional Review Board (IRB #43239) and all the study participants provided informed consent. The protocol for the study was registered on clinicaltrials.gov (NCT02849639) on 29/07/2016, in accordance with the relevant guidelines and regulations or in accordance with the Declaration of Helsinki. Study data were collected and managed using the Research Electronic Data Capture (REDCap), a secure, web-based software platform designed to support data capture for research studies [14 (link), 15 (link)].
The INCREASE study was approved by the University of Kentucky Institutional Review Board (IRB #43239) and all the study participants provided informed consent. The protocol for the study was registered on clinicaltrials.gov (NCT02849639) on 29/07/2016, in accordance with the relevant guidelines and regulations or in accordance with the Declaration of Helsinki. Study data were collected and managed using the Research Electronic Data Capture (REDCap), a secure, web-based software platform designed to support data capture for research studies [14 (link), 15 (link)].
Adult
Aged
Amyloid Proteins
Dementia
Neurologists
Pharmaceutical Preparations
Polypharmacy
Practitioner, Nurse
The following baseline measurements were analysed: age, sex, Body Mass Index (BMI), American Society of Anaesthesiology Physical Score (ASA PS), quantity of preoperative long-term agents taken by the patient, polypharmacy defined as more than five preoperative long-term agents, Anti-cholinergic Drug Scale (ADS) of the long-term agents, type of surgery, incision-suture time, applied volume of placebo or dexmedetomidine.
Complementary to the baseline characteristics, opioid, anaesthetic, and red blood cell transfusion requirements were recorded from the intraoperative data as potential influencing factors on cholinesterase activities.
Complementary to the baseline characteristics, opioid, anaesthetic, and red blood cell transfusion requirements were recorded from the intraoperative data as potential influencing factors on cholinesterase activities.
Action Potentials
Anesthetics
Anticholinergic Agents
Cholinesterases
Dexmedetomidine
Index, Body Mass
Operative Surgical Procedures
Opioids
Patients
Physical Examination
Placebos
Polypharmacy
Red Blood Cell Transfusion
Sutures
The European guidelines on POD suggested that baseline assessment includes cognitive, functional and mental function,16 (link) so the QC-POD intervention begins with the first contact with patients in the anaesthesiology outpatient clinic. This intervention involves screening for predisposing and precipitating risk factors for POD,9 16 29 (link) as well as employing a screening to detect delirium before surgery. Our intervention also includes the results of a minigeriatric assessment, including a modified Fried frailty assessment30 (link) with questions on unintentional weight loss, fatigue, physical activity measured by metabolic equivalents, measurement of hand strength with a dynamometer and measurement of gait speed.30 31 (link) In addition, the Timed Up and Go Test is performed at baseline, along with information regarding the patient’s history of falls.32 (link) The social situation is assessed with a questionnaire created by Nikolaus et al (SOS-I)33 (link); nicotine consumption with Heaviness of Smoking Index,34 (link) and alcohol consumption with Alcohol use Disorders Identification Test-Consumption Items35 36 (link) are also recorded with a specific questionnaire. Furthermore, the assessment of an existing polypharmacy and check for anticholinergic medication,37 38 (link) the health questionnaire (Patient Health Questionnaires-8, PHQ-8) for signs of depression,39 (link) and a mini-cognitive test (clock drawing test, three-word memory test) are included. Anxiety or stress is measured with the self-assessment tool Faces Anxiety Scale,40 41 (link) and pain with the 0-10 visually Numeric Rating Scale (NRS-V).42 (link)
Alcohol Use Disorder
Anticholinergic Agents
Anxiety
Cognition
Cognitive Testing
Delirium
Europeans
Face
Fatigue
Memory
Metabolic Equivalent
Nicotine
Operative Surgical Procedures
Pain
Patients
Polypharmacy
Self-Assessment
Patient information at the time of SDM implementation was retrospectively obtained from the medical records. The surveyed items were sex, age (years), age (<65 years/≥65 years), RA, multiple rheumatic diseases, disease duration (years), disease duration (<10/≥10 years), disease activity (active/inactive), number of drugs used (number), number of drugs used (<5/≥5), history of allergy or side effects, history of allergy or side effects due to biologics or Janus kinase inhibitor, biologics, or Janus kinase inhibitor usage history before SDM. Age was classified into two categories according to the World Health Organization (WHO). Disease duration was classified into two categories based on a previous report on RA (12 (link)). Disease activity was classified into two categories; patients with RA were categorized as inactive if they exhibited low disease activity or remission based on their DAS28-CRP value and as active if they exhibited moderate or high disease activity. Those with other rheumatic diseases were classified as inactive if clinically judged by a physician to be in remission or have low disease activity and as active if they were otherwise judged to have moderate or higher-intensity symptoms. The number of drugs used was classified into two categories based on a previous report on polypharmacy (13 (link)).
The influential values of patients regarding drug treatment were compiled from subjective data describing values chosen by patients during conversations between pharmacists and patients during SDM implementation. The values compiled were multiple selected and single selected from the five values: effectiveness, safety, economic, daily life (drug treatment burden on life), and others (such as route of administration, type of device).
The continuance rate of treatment 6 months after SDM and disease status (improvement, aggravation, and no change) were evaluated, with reasons including inadequate effectiveness, side effects, economic issues, daily life issues, and other issues among patients.
The details of the drug treatment changes selected after the implementation of SDM were tabulated. The results included changing the drugs, tight control, no change, drug use cessation, increased dosage, change in the route of administration, addition of an oral drug, oral drug cessation, reduced dosage, changes in oral drug, and shortening of the interval between doses.
Because SDM was performed in the usual clinical setting, the pharmacists were not blinded to the outcomes, such as the continuance rate of treatment.
The influential values of patients regarding drug treatment were compiled from subjective data describing values chosen by patients during conversations between pharmacists and patients during SDM implementation. The values compiled were multiple selected and single selected from the five values: effectiveness, safety, economic, daily life (drug treatment burden on life), and others (such as route of administration, type of device).
The continuance rate of treatment 6 months after SDM and disease status (improvement, aggravation, and no change) were evaluated, with reasons including inadequate effectiveness, side effects, economic issues, daily life issues, and other issues among patients.
The details of the drug treatment changes selected after the implementation of SDM were tabulated. The results included changing the drugs, tight control, no change, drug use cessation, increased dosage, change in the route of administration, addition of an oral drug, oral drug cessation, reduced dosage, changes in oral drug, and shortening of the interval between doses.
Because SDM was performed in the usual clinical setting, the pharmacists were not blinded to the outcomes, such as the continuance rate of treatment.
Biological Factors
Hypersensitivity
Kinase Inhibitor, Janus
Medical Devices
Patients
Pharmaceutical Preparations
Physicians
Polypharmacy
Rheumatism
Safety
The Population Health Index (PHI) survey is a longitudinal survey to examine the health of community- dwelling adult population in the Central region of Singapore. Details of the study have been described previously.16 (link) In brief, the PHI survey used a standardised survey questionnaire to collect information on demographic and socioeconomic characteristics, physical and mental health status, functional and nutritional status, cognition status and medication usage.16 (link) A sampling frame of residential dwelling units was constructed by matching postal codes in the National Database on Dwellings in Singapore with the list of postal codes for the central region.16 (link) Within each planning area, a sample of dwelling units was selected proportionately from defined dwelling type groups. One eligible household member (Singaporean or permanent residents aged 21 years and above, staying in the household for >6 months) was randomly selected using the Kish grid.17 (link)
Between November 2015 and November 2016, trained interviewers carried out baseline face-to-face survey.16 (link) A total of 1942 individuals participated in the baseline survey, of which, 1526 participants completed 1-year follow-up survey between November 2016 and December 2017 (retention rate: 78.6%). For this study, we included only participants aged 40 years and above at baseline (N=1451). We excluded participants with missing baseline information on polypharmacy, vision and hearing impairment, alcohol intake, depression status, self-reported pain, loneliness status, and frailty status, and information on falls at 1-year follow-up (N=315). We further excluded participants who have experienced a fall prior to the baseline examination (n=83). The final analytical sample comprised of 1053 participants. Baseline characteristics of those who were included and excluded from the data analysis are shown inonline supplemental table S1 . The study was approved by the research ethics committee of the National Healthcare Group. Written informed consent was obtained from each participant before enrolment and the conduct of the study adhered to the Declaration of Helsinki.
Between November 2015 and November 2016, trained interviewers carried out baseline face-to-face survey.16 (link) A total of 1942 individuals participated in the baseline survey, of which, 1526 participants completed 1-year follow-up survey between November 2016 and December 2017 (retention rate: 78.6%). For this study, we included only participants aged 40 years and above at baseline (N=1451). We excluded participants with missing baseline information on polypharmacy, vision and hearing impairment, alcohol intake, depression status, self-reported pain, loneliness status, and frailty status, and information on falls at 1-year follow-up (N=315). We further excluded participants who have experienced a fall prior to the baseline examination (n=83). The final analytical sample comprised of 1053 participants. Baseline characteristics of those who were included and excluded from the data analysis are shown in
Adult
Cognition
Ethics Committees, Research
Face
Hearing Impairment
Households
Infantile Neuroaxonal Dystrophy
Interviewers
Pain
Pharmaceutical Preparations
Physical Examination
Polypharmacy
Population Health
Reading Frames
Respiratory Diaphragm
Retention (Psychology)
Vision
Top products related to «Polypharmacy»
Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India
SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.
Sourced in United States, Austria, Japan, Belgium, United Kingdom, Cameroon, China, Denmark, Canada, Israel, New Caledonia, Germany, Poland, India, France, Ireland, Australia
SAS 9.4 is an integrated software suite for advanced analytics, data management, and business intelligence. It provides a comprehensive platform for data analysis, modeling, and reporting. SAS 9.4 offers a wide range of capabilities, including data manipulation, statistical analysis, predictive modeling, and visual data exploration.
Sourced in United States, Austria, Japan, Belgium, Brazil, United Kingdom, Cameroon
SAS software version 9.4 is a comprehensive data analysis and management solution. It provides advanced statistical and analytical capabilities for organizations to manage, analyze, and report on their data. The software includes a range of tools and features to support various data-driven tasks, such as data manipulation, statistical modeling, and predictive analytics.
Sourced in United States, United Kingdom, Austria, Denmark
Stata 15 is a comprehensive, integrated statistical software package that provides a wide range of tools for data analysis, management, and visualization. It is designed to facilitate efficient and effective statistical analysis, catering to the needs of researchers, analysts, and professionals across various fields.
Sourced in United States, Denmark, United Kingdom, Belgium, Japan, Austria, China
Stata 14 is a comprehensive statistical software package that provides a wide range of data analysis and management tools. It is designed to help users organize, analyze, and visualize data effectively. Stata 14 offers a user-friendly interface, advanced statistical methods, and powerful programming capabilities.
Sourced in United States, Japan, Hong Kong, United Kingdom, Germany, Denmark
PASW Statistics 18 is a statistical analysis software package developed by IBM. It is designed to facilitate data management, analysis, and visualization tasks. The software provides a range of statistical procedures and tools to assist users in examining relationships, identifying trends, and making informed decisions based on data.
Sourced in United States, United Kingdom, Belgium, Japan, Austria, Germany, Denmark
SPSS Statistics for Windows is an analytical software package designed for data management, analysis, and reporting. It provides a comprehensive suite of tools for statistical analysis, including regression, correlation, and hypothesis testing. The software is intended to assist users in gaining insights from their data through advanced analytical techniques.
Sourced in United States, Denmark, United Kingdom, Austria, Sweden
Stata 13 is a comprehensive, integrated statistical software package developed by StataCorp. It provides a wide range of data management, statistical analysis, and graphical capabilities. Stata 13 is designed to handle complex data structures and offers a variety of statistical methods for researchers and analysts.
Sourced in United States, Denmark, Austria, United Kingdom, Japan, Canada
Stata version 14 is a software package for data analysis, statistical modeling, and graphics. It provides a comprehensive set of tools for data management, analysis, and reporting. Stata version 14 includes a wide range of statistical techniques, including linear regression, logistic regression, time series analysis, and more. The software is designed to be user-friendly and offers a variety of data visualization options.
Sourced in United States, United Kingdom, Belgium, Japan
SPSS Statistics for Windows, Version 21.0 is a statistical software package designed for data analysis. It provides a comprehensive set of tools for data manipulation, analysis, and visualization. The software is designed to work on the Windows operating system.
More about "Polypharmacy"
Polypharmacy is the concurrent use of multiple medications by a patient, often associated with older adults and individuals with chronic conditions.
This complex medical issue, also known as multipharmacy or excessive polypharmacy, can lead to adverse drug interactions, increased risk of side effects, and reduced medication adherence.
Effective management of polypharmacy requires careful consideration of patient-specific factors, medication interactions, and the potential benefits and risks of each prescription.
Healthcare providers play a crucial role in optimizing polypharmacy through regular medication reviews, patient education, and coordinated care.
Research in this area focuses on developing tools and strategies, such as those provided by SAS version 9.4, Stata 15, PASW Statistics 18, and SPSS Statistics for Windows, to help identify and mitigate the challenges of polypharmacy, with the ultimate goal of improving patient outcomes and quality of life.
Key subtopics related to polypharmacy include medication management, adverse drug events, drug-drug interactions, medication adherence, geriatric pharmacology, and care coordination.
Understanding and effectively managing polypharmacy is essential for healthcare professionals in SAS 9.4, Stata 14, SPSS Statistics for Windows, Version 21.0, and other medical and research settings to ensure optimal patient care and safety.
This complex medical issue, also known as multipharmacy or excessive polypharmacy, can lead to adverse drug interactions, increased risk of side effects, and reduced medication adherence.
Effective management of polypharmacy requires careful consideration of patient-specific factors, medication interactions, and the potential benefits and risks of each prescription.
Healthcare providers play a crucial role in optimizing polypharmacy through regular medication reviews, patient education, and coordinated care.
Research in this area focuses on developing tools and strategies, such as those provided by SAS version 9.4, Stata 15, PASW Statistics 18, and SPSS Statistics for Windows, to help identify and mitigate the challenges of polypharmacy, with the ultimate goal of improving patient outcomes and quality of life.
Key subtopics related to polypharmacy include medication management, adverse drug events, drug-drug interactions, medication adherence, geriatric pharmacology, and care coordination.
Understanding and effectively managing polypharmacy is essential for healthcare professionals in SAS 9.4, Stata 14, SPSS Statistics for Windows, Version 21.0, and other medical and research settings to ensure optimal patient care and safety.